Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE

Author:

Monserrat Fuertes Teresa,Santos Zorrozua Borja,Rodeño Ortiz de Zarate Emilia,Peinado Montes Miguel Ángel,Vigil Díaz Carmen,Mínguez Gabiña PabloORCID

Abstract

Abstract Background As for any other nuclear medicine treatment, patients treated with [177Lu]Lu-DOTA-TATE should be given some radiation protection recommendations after being discharged to limit the dose received by family members and public. The restriction periods will depend on the remaining activity at the time of discharge, the washout rate and patients’ personal conditions. The activity in patients’ whole-body follows a bi-exponential behaviour. At the time of discharge only the first part of the time-activity curve is known. However, the second phase of the bi-exponential curve should be known to individualize the time of restrictions. The main purpose of this prospective study was to establish a simple method for calculating the restriction periods based on measurements taken before discharge. Methods The whole-body time-activity curve was calculated for 20 patients from dose-rate measurements performed during the first week post-administration. An effective decay time $$T_{{{\text{eff}}}}^{6,24}$$ T eff 6 , 24 was calculated from a mono-exponential fit performed with the 6 h and 24 h measurements and compared with the effective decay time $$T_{{{\text{eff}}}}^{24,48,168}$$ T eff 24 , 48 , 168 obtained from the mono-exponential fit performed with the 24 h, 48 h and 168 h measurements. The differences between them were calculated and the 95th percentile of these differences was used as a correction factor for $$T_{{{\text{eff}}}}^{6,24}$$ T eff 6 , 24 . A modified effective decay $$T_{{{\text{eff}},{\text{ mod}}}}^{6,24}$$ T eff , mod 6 , 24 was obtained by adding the correction factor to $$T_{{{\text{eff}}}}^{6,24}$$ T eff 6 , 24 and the restriction periods for each patient was calculated. The whole body activity washout between the first and the fourth treatment cycles of 16 patients was also compared. Results The comparison of the whole-body activity curves between the first and the fourth cycle of the treatment for 16 patients would indicate that the recommendations on radiation protection determined from the first cycle could reasonably be used for the remaining cycles in most patients. The values of $$T_{{{\text{eff}}}}^{6,24}$$ T eff 6 , 24 and $$T_{{{\text{eff}}}}^{24,48,168}$$ T eff 24 , 48 , 168 obtained for the 20 patients were significantly different. The 95th percentile of the differences between $$T_{{{\text{eff}}}}^{6,24}$$ T eff 6 , 24 and $$T_{{{\text{eff}}}}^{24,48,168}$$ T eff 24 , 48 , 168 was 46 h, which is thus the time to be added to $$T_{{{\text{eff}}}}^{6,24}$$ T eff 6 , 24 so as to determine the restriction periods. Conclusions The proposed method makes it possible to calculate the restriction periods for patients treated with [177Lu]Lu-DOTA-TATE before they leave the hospital in a conservative and individualized way.

Funder

Eusko Jaurlaritza

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,Instrumentation,Biomedical Engineering,Radiation

Reference27 articles.

1. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–62.

2. BNM-LNHB/CEA-Table de radionucléides-177Lu [Internet]. Laboratoire National Henri Becquerel. Available from: http://www.nucleide.org/DDEP_WG/Nuclides/Lu-177_tables.pdf.

3. ICRP Publication 94. Release of patients after therapy with unsealed radionuclides. Stockholm: Elsevier; 2004.

4. ICRP Publication 103. The 2007 recommendations of the International Commission on Radiological Protection. Oxford: Elsevier; 2007.

5. Levart D, Kalogianni E, Corcoran B, Mulholland N, Vivian G. Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours. EJNMMI Phys. 2019;6:7.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3